Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are small-molecule therapies that inhibit the intracellular tyrosine kinase activity of the EGFR (EGFR, also known as ERBB1).
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are small-molecule therapies that inhibit the intracellular tyrosine kinase activity of the EGFR (EGFR, also known as ERBB1). EGFR activation normally promotes receptor phosphorylation and downstream signaling through pathways such as RAS–RAF–MEK–ERK and PI3K–Protein kinase B (PKB), which regulate cell proliferation, survival, migration, and differentiation. By occupying the receptor’s ATP-binding pocket, EGFR-TKIs reduce EGFR autophosphorylation and can suppress growth of tumors dependent on EGFR signaling.
EGFR-TKIs have particular clinical and experimental importance in molecularly selected non-small-cell lung cancer (NSCLC), especially tumors containing activating EGFR alterations. Commonly studied agents include gefitinib and erlotinib, while later-generation inhibitors have been developed to address selected resistance mechanisms. Their activity can be influenced by tumor genotype, EGFR amplification, pathway reactivation, and acquired resistance. EGFR-TKI treatment is also associated with characteristic adverse effects, including skin rash; however, the clinical interpretation of rash as a marker of treatment benefit requires careful consideration of time-dependent biases. EGFR-TKIs are additionally investigated in combination with other targeted therapies, including KRAS G12C inhibitors, anti-EGFR antibodies, antibody–drug conjugates, antiangiogenic agents such as bevacizumab, and strategies targeting autophagy or ferroptosis.
Where the papers sit
8 papers from the last 6 months study Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 2 observational · 2 human data · 4 preclinical
Themes 3 themes
-
EGFR Resistance in Lung Cancer
EGFR-TKI treatment in EGFR-mutant NSCLC is being refined through early-risk prediction and mechanisms of drug tolerance. ULK1 inhibition may delay tolerance, while acquired resistance and early progression remain central problems. Skin rash may associate with mortality, although body mass index and pleural effusion complicate real-world interpretation. Amphiregulin-mediated EGFR activation also links EGFR signaling to resistance to KRAS G12C inhibitors.
4 papers · 50%
-
Natural-Product EGFR Inhibitors
Natural products and semi-synthetic derivatives are being screened as EGFR tyrosine kinase inhibitors. Nogalamycin compounds, withacoagulin, and Moringa oleifera-derived glycosides recur as candidate antiproliferative agents. Molecular docking and molecular dynamics are paired with in vitro testing to connect predicted binding with kinase inhibition. The main open question is whether these computationally supported hits can achieve validated cellular and therapeutic activity.
3 papers · 37.5%
-
EGFR-Amplified Tumoroid Biology
EGFR amplification is being examined as a defining feature of squamous carcinoma of unknown primary. Fluorescence in situ hybridization and exome sequencing establish the tumour’s molecular profile. Functional growth-inhibition testing in a patient-derived tumoroid links that profile to drug response. The model provides a platform for testing EGFR-directed treatment in this rare, molecularly selected cancer.
1 papers · 12.5%
Papers
The 8 papers from the last 6 months that study Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
EGFR Resistance in Lung Cancer (4)
- Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study. Medicine · 31 Jul 2026 PMID 42536589
- ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model. Lung cancer (Amsterdam, Netherlands) · 6 Jul 2026 PMID 42407241
- Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene · 2 Jul 2026 PMID 42393288
- Association Between EGFR-TKI-Associated Skin Rash and Recorded Mortality in Non-Small Cell Lung Cancer: A Real-World Analysis Accounting for Immortal Time Bias. Pharmacoepidemiology and drug safety · 1 Jul 2026 PMID 42381293
Natural-Product EGFR Inhibitors (3)
- Valorization of Moringa oleifera pericarp via semi-synthetic sugar-based enone derivatives with anticancer potential: phytochemical isolation, cytotoxic evaluation, and dual EGFR/CAIX targeting. Scientific reports · 4 Jul 2026 PMID 42401652
- Identification of antiproliferative nogalamycin series as potent inhibitors of EGFR tyrosine kinase: An in vitro and computational study. Chemico-biological interactions · 23 Jun 2026 PMID 42336028
- EGFR tyrosine kinase inactivation by Withacoagulin-induced conformational shift. Journal of molecular graphics & modelling · 13 Jun 2026 PMID 42287988
EGFR-Amplified Tumoroid Biology (1)
- Establishment and functional characterization of an EGFR-amplified tumoroid from squamous cell carcinoma of unknown primary. Human cell · 19 Aug 2026 PMID 42616271
By study type
Observational studies and case reports (2)
- Baseline predictors of early progression during EGFR-TKI therapy in patients with EGFR-mutant non-small cell lung cancer: A retrospective cohort study. Medicine · 31 Jul 2026 PMID 42536589
- Association Between EGFR-TKI-Associated Skin Rash and Recorded Mortality in Non-Small Cell Lung Cancer: A Real-World Analysis Accounting for Immortal Time Bias. Pharmacoepidemiology and drug safety · 1 Jul 2026 PMID 42381293
Human data, design not indexed (2)
- Valorization of Moringa oleifera pericarp via semi-synthetic sugar-based enone derivatives with anticancer potential: phytochemical isolation, cytotoxic evaluation, and dual EGFR/CAIX targeting. Scientific reports · 4 Jul 2026 PMID 42401652
- EGFR tyrosine kinase inactivation by Withacoagulin-induced conformational shift. Journal of molecular graphics & modelling · 13 Jun 2026 PMID 42287988
Preclinical: animal, cell and lab studies (4)
- Establishment and functional characterization of an EGFR-amplified tumoroid from squamous cell carcinoma of unknown primary. Human cell · 19 Aug 2026 PMID 42616271
- ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer model. Lung cancer (Amsterdam, Netherlands) · 6 Jul 2026 PMID 42407241
- Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene · 2 Jul 2026 PMID 42393288
- Identification of antiproliferative nogalamycin series as potent inhibitors of EGFR tyrosine kinase: An in vitro and computational study. Chemico-biological interactions · 23 Jun 2026 PMID 42336028
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-08-23. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.